Bortezomib for previously untreated mantle cell lymphoma

  • Technology appraisal guidance
  • TA370
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Kleijnen Systematic Reviews:

  • Wolff R, Ramaekers B, van Dongen-Leunis A, et al., Bortezomib for previously untreated mantle cell lymphoma: a Single Technology Appraisal, September 2015

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope. Organisations listed in I were also invited to make written submissions. Organisations listed in II gave their expert views on bortezomib by making a submission to the Committee. Organisations listed in I, II and III have the opportunity to appeal against the final appraisal determination.

I. Company

  • Janssen

II. Professional/expert and patient/carer groups:

  • British Society for Haematology

  • Cancer Research UK

  • Leukaemia CARE

  • Lymphoma Association

  • Royal College of Pathologists

  • Royal College of Physicians

  • UK Clinical Pharmacy Association

III. Other consultees:

  • Department of Health

  • NHS England

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • National Collaborating Centre for Cancer

  • Roche Products (rituximab)

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on bortezomib by providing oral evidence to the Committee.

  • Professor Simon Rule, Consultant Haematologist/Professor of Clinical Haematology, nominated by organisation representing Janssen and Royal College of Physicians – clinical expert

  • Ms Katharine Robinson, nominated by organisation representing Lymphoma Association – patient expert

D. Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Janssen